As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Quibiotic SAS

Pépinière Genopole Entreprises
Campus 3 – 4 rue Pierre Fontaine
Tel: +33 (0)7 83 77 23 29

CEO: Paolo Bonomi
Quibiotic - Projet Shaker Quibiotic - Projet Shaker

#HealthTech #Innovative therapies

  • Innovation
  • Synthesis
  • Platforms
  • Beta-lactam ring
  • Anti-infectives

Domaine d'activité

Quibiotic develops three molecular synthesis platforms aimed at innovatively modifying β-lactam rings for new anti-infectives.

The roots of Quibiotic’s technology are to be found in an initial independent patent filed in 2016 by Paolo Bonomi. The base concept of the Quibiotic project is to reconsider lactam rings with the goal of developing novel therapeutics. In 2018, a second Italian patent was filed, in 2019, the project was selected for the Genopole Shaker program and in 2020 a third patent was filed. Thereafter, Quibiotic was officially created on 10 October 2021 by four associates with complementary competencies.


Quibiotic proposes three molecular synthesis platforms for the chemical modification of β-lactam rings in only three to four steps. The company’s technology makes it possible to link any given biologically active molecule to the β-lactam ring. Experimental trials have demonstrated class D β-lactamase inhibition activity for a first molecule and antineoplastic activity for a second one.


A project is currently underway in partnership with the University of Évry-Paris Saclay and Professor N. Jarroux at Lambe to study the complexation of different substrates with cyclodextrins. The goal of this work is to modulate the bioavailability or the activity of our novel compounds.
We are actively seeking project partnerships with public and/or private institutions to empower the development of our platforms and to enable symbiotic relations with other technologies complementary to ours.

  • Further information

    3 patents

    Innovation in molecular synthesis strategies. Creation of a library of novel compounds. Simple chemical steps. Expertise in chemistry & biology + complementary competencies among the associates and an advisory board.

    Innovation assets
    A new way of thinking about β-lactam matrices.

    Other facts
    Passion, dedication and ethics.

Genopole’s companies

#Industrial Biotech

In the same filed

The VERY Food Co

Activity of research, sale, production, distribution and marketing of all unregulated food and agri-food products.

STH Biotech - Genopole's company

STH Biotech

STH BIOTECH is developing an innovative cannabis-based process for the reliable and sustainable production of active compounds for the well-being and healthcare sectors.

Synovance - entreprise généopolitaine


Synovance has developed a revolutionary synthetic genomics platform for the conception of robust industrial bioproduction strains.

Altar - entreprise génopolitaine - intégre le groupe Ginko Bioworks


Ginkgo Bioworks is a specialist in the conception and operation of automated fluidic continuous culture systems for adaptive laboratory evolution and the development of microbial strains for industry.

Yposkesi - Genopole's Company


YposKesi is the first French company to develop and manufacture gene and cell therapy products for rare diseases.

Watchfrog Laboratory - Genopole's company


WatchFrog markets in vivo biotechnological solutions for environmental risk assessment and the evaluation of the therapeutic, toxic or pollutant potential of all types of chemical, cosmetic or pharmaceutical compounds.

Pharming - Genopole's company - Logo 2021


Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.

Global Bioenergies - entreprise génopolitaine - logo 2022

Global Bioenergies

Global Bioenergies is developing a process to convert renewable resources into hydrocarbons through fermentation.

ABOLIS - entreprise génopolitaine

Abolis Biotechnologies

Abolis develops custom-order microorganisms able to produce molecules of interest via fermentation for the health, nutrition, chemistry and cosmetics sectors.

View all >
With the support from
Région île de France